This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period from May 1, 2024 to April 30, 2026. This award represents the agency's strategic efforts to advance medical solutions for military service members and the broader public through impactful biomedical research projects.
Generated 1/28/25, 7:31 AM